EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSOGAG00000000699
Gene Symbol: GABRA5
4 Cross references
262 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSOGAG00000010680
Gene Symbol: GABRA6
4 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSOGAG00000029275
Gene Symbol: GABRB2
2 Cross references
272 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSOGAG00000000698
Gene Symbol: GABRB3
2 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSOGAG00000016670
Gene Symbol: GABRD
4 Cross references
193 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Epsilon

Ensembl ID : ENSOGAG00000002940
Gene Symbol: GABRE
2 Cross references
111 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSOGAG00000012723
Gene Symbol: GABRG1
2 Cross references
188 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSOGAG00000010687
Gene Symbol: GABRG2
4 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Pi

Ensembl ID : ENSOGAG00000013604
Gene Symbol: GABRP
4 Cross references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Theta

Ensembl ID : ENSOGAG00000013172
Gene Symbol: GABRQ
4 Cross references
87 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSOGAG00000000076
Gene Symbol: GABBR1
2 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSOGAG00000006114
Gene Symbol: GABBR2
2 Cross references
241 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).